Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: David Shaywitz

Premium

DNAnexus has hired David Shaywitz to be its chief medical officer.

Shaywitz joins DNAnexus from Theravance Biopharma where he focused on strategy and business development, and led a product team. Prior to that, he was a management
consultant at the Boston Consulting Group, and was a member of the department of experimental medicine at Merck Research Labs. He is also a co-founder of the Pasteur translational research program at Harvard Medical School; and a founding advisor of Sage Bionetworks.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.